Personalized Medicine testing recommendations for:

Colorectal Cancer

Newly Diagnosed Stage I-III (somatic)

When and what should be tested?

- Treatment eligible
- Stage I-III
- Newly diagnosed to make determination on adjuvant therapy as well as choice of regimen
- Tissue sample preferred
- Liquid biopsy if tissue sample inadequate for further testing

FDA/NCCN approved

- MLH1
- MSH2
- MSH6 or PMS2 for loss of protein expression via IHC
- MSI via PCR
- MRD
- MMR
- POLE/POLD1 with hypermutated phenotype (e.g., TMB>50)

Emerging

- cfDNA for MRD assessment/Oncotype DX (stage II-III)
- Consider PIK3CA

Assume CEA testing at initial diagnosis and ongoing monitoring will be conducted as standard of care. Initial evaluation of CEA will be an important monitoring consideration

cencora

Personalized Medicine testing recommendations for:

Colorectal Cancer

Newly Diagnosed Advanced Disease or Progression on Treatment (somatic)

When and what should be tested?

- Treatment eligible
- Stage IV (newly diagnosed, advanced, or progressed on treatment
- Tissue sample preferred
- Liquid biopsy if tissue sample inadequate for further testing



FDA/NCCN approved

- Limited panel including:
  - KRAS
  - KRAS G12C
  - NRAS
  - BRAF / BRAF V600E
  - HER2 (via IHC+, FISH, or NGS)
  - TMB ≥50 mut/Mb
  - MSI
  - dMMR
  - NTRK
  - RET
  - POLE/POLD1 mutation
  - MRD

Emerging

- Comprehensive NGS panel

Complete appropriate diagnostic testing for all patients as outlined in this recommendation

cencora

Personalized Medicine testing recommendations for:

Colorectal Cancer

Prior to Second Line Therapy with I/O Agent (somatic)

When and what should be tested?

- Treatment eligible
- All patients prior to second line therapy with I/O agent
- Tissue sample preferred
- Liquid biopsy if tissue sample inadequate for further testing

FDA/NCCN approved

- Limited panel including:
  - MSI (for each metastatic lesion)
  - dMMR
  - NTRK
  - TMB
  - POLE/POLD1
  - MRD

Emerging

- Comprehensive NGS panel

Complete appropriate diagnostic testing for all patients as outlined in this recommendation

cencora

Personalized Medicine testing recommendations for:

Colorectal Cancer

Genetic High-Risk Patients

When and what should be tested?

- Histologically verified colorectal cancer in 3 relatives, at least one first degree relative
- Colorectal cancer in two successive generations
- At least one member being younger than 50 years
- Upon treatment by a medical oncologist
- Peripheral blood for germline mutation
- Tissue analysis

FDA/NCCN approved

- Testing for Lynch Syndrome*
- MLH1, MSH2, MSH6 or PMS2 via IHC test
- MLH1, MSH2, MSH6, PMS2 mutation or EPCAM (TACSTD1) mutation, MSI via PCR test
- If abnormal IHC or MSI, then MLH1 promoter methylation, EPCAM mutation or BRAF V600E should be tested

Emerging

- n/a

* MSI may be indicative of Lynch Syndrome, yet not diagnostic

If previously seen by a gastroenterologist, then testing of Lynch Syndrome should already have been conducted. If not, follow the recommendations above

cencora